ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 1.7.2 (20 November 2019) - 2999001/03328426CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120210602W154deBibliographieenBibliographyfrBibliographieEP16753597.0201607272018022620190104enenen1517848920150727EP2021060220212220180606201823202104072021142020101520210602202122A61K 45/06 20060101AFI20200817BHEP A61K 31/337 20060101ALI20200817BHEP A61K 31/517 20060101ALI20200817BHEP A61K 33/24 20190101ALI20200817BHEP A61P 35/00 20060101ALI20200817BHEP A61K 31/7068 20060101ALI20200817BHEP A61K 33/243 20190101ALI20200817BHEP C12Q 1/6886 20180101ALI20200817BHEP G01N 33/574 20060101ALI20200817BHEP A61K 39/395 20060101ALI20200817BHEP C07K 16/32 20060101ALI20200817BHEP deBEHANDLUNG VON PATIENTEN MIT DIAGNOSTIZIERTEM DUKTALEN ADENOKARZINOM DES PANKREAS MIT MONOKLONALEN ANTIKÖRPERN GEGEN DEN EPIDERMALEN WACHSTUMSFAKTOR REZEPTOR (EGFR)enTREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)frTRAITEMENT DES PATIENTS DIAGNOSTIQUÉS AVEC UN ADÉNOCARCINOME CANALAIRE PAR DES ANTICORPS MONOCLONAUX CONTRE LE RECEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUEEP-A1- 2 070 547WO-A1-2013/138371WO-A1-2014/095766Sideways: "EGFR inhibition is effective against KRAS-wild-type disease | Nature Reviews Clinical Oncology", Nature reviews clinical oncology, 25 July 2017 (2017-07-25), XP55536776, Retrieved from the Internet: URL:https://www.nature.com/articles/nrclin onc.2017.119 [retrieved on 2018-12-19]B. SCHULTHEIS ET AL: "Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study", ANNALS OF ONCOLOGY., vol. 28, no. 10, 6 July 2017 (2017-07-06), pages 2429-2435, XP055652203, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdx343STRUMBERG, DirkMarienhospital Herne Abt. für Hämatologie und Onkologie Hoelkeskampring 4044621 HerneDESCHULTHEIS, BeateUniversity Bochum Marien Hospital HerneHerneDEEBERT, Matthias, P.Klinikum rechts der Isar TU MünchenMunichDESIVEKE, JensKlinikum rechts der Isar TU MünchenMunichDEKERKHOFF, AndreaUniversity Hospital MuensterMuensterDEHOFHEINZ, RalfDepartment of Hematology and Medical Oncology University Medical Center MannheimMannheimDEBEHRINGER, Dirk, M.Augusta-Kranken-AnstaltBochumDESCHMIDT, Wolfgang, E.St. Josef Hospital Med. Klinik IBochumDEGOKER, ErdemEge University Medical SchoolIzmirTRDE DOSSO, SaraOncology Institute of Southern SwitzerlandBellinzonaCHKNEBA, MichaelDepartment of Medicine University Medical Center Schleswig-HolsteinKielDEYALCIN, SuayibHacettepe University HospitalAnkaraTROVERKAMP, FriedrichMedical Practice for Oncology and HematologyRecklinghausenDESCHLEGEL, FrankSt. Antonius HospitalEschweilerDEDOMMACH, MarkusSana-Kliniken Medizinisches Versorgungszentrum OnkologieDuesseldorfDEROHRBERG, RobertGemeinschaftspraxis und Tagesklinik fuer Haematologie Onkologie und GastroenterologieHalleDESTEINMETZ, TilmanGroup Practice Hematology/Oncology CologneCologneDEBACH, Ferdinandc/o Oncoscience AG Hafenstrasse 3222880 WedelDEREUTER, Dirkc/o Oncoscience AG Hafenstrasse 3222880 WedelDEILYAS, Rikrik, Asiyahc/o InnoCIMAb Pte Ltd 21 Bukit Batok Crescent 14-78 WCEGA TowerSingapore 658065SGIZNAGA ESCOBAR, Normando, E.c/o InnoCIMAb Pte Ltd 21 Bukit Batok Crescent 14-78 WCEGA TowerSingapore 658065SGInnoCIMAb Pte Ltd101538669INN15364PCTEPWCEGA Tower No. 14-78, 21 Bukit BatokSingapore 659065SGOncoscience AG101648313INN15364PCTEPHafenstrasse 3222880 WedelDESchiweck Weinzierl Koch Patentanwälte Partnerschaft mbB101223256Ganghoferstraße 68 B80339 MünchenDEALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTREP201606789220160727enWO201701713320170202201705